Tag
Anupam Rasayan India Limited
5 articles
Anupam Rasayan is strategically expanding its pharmaceutical capabilities through a significant acquisition of Bliss GVS Pharma, aiming to bolster its integrated value chain and access new therapeutic areas and regulated markets. The company plans to fund the acquisition, which includes a mandatory open offer, through a combination of term loans and non-voting equity. Alongside this transformative deal, Anupam Rasayan reported a substantial 122% year-over-year increase in net profit for fiscal year 2026 and approved a 15% final dividend. However, the resignation of Deputy CFO Vishal Thakkar introduces a degree of uncertainty, though he intends to pursue opportunities within the broader group.
Anupam Rasayan First Global ETFA Flow Chemistry Commercialization
Anupam Rasayan commercialized ETFA production using proprietary flow chemistry, becoming the first company globally to achieve this.
The global addressable market for ETFA is estimated at USD 500-600
Anupam Rasayan Mandatory Open Offer for 26% Bliss GVS
Anupam Rasayan India Limited discloses Draft Letter of Offer for mandatory open offer to acquire 26% of Bliss GVS Pharma Limited's expanded voting capital at ₹299 per share.
Open offer triggered by Sh
Anupam Rasayan Open Offer for 26% of Bliss GVS
Anupam Rasayan India Limited makes a mandatory open offer to acquire up to 2.77 crore equity shares, representing 26% of Bliss GVS Pharma's expanded voting capital, at ₹299 per share.
The open offer,
Anupam Rasayan Open Offer for 26% Bliss GVS Pharma
Anupam Rasayan India Limited makes a mandatory open offer to acquire up to 2,77,26,848 equity shares (26.00%) of Bliss GVS Pharma Limited at ₹299 per share, triggered by a Share Purchase Agreement dat
Anupam Rasayan Open Offer for 26% Bliss GVS
Anupam Rasayan India Limited launched a mandatory open offer for 26% of Bliss GVS Pharma's expanded voting capital at ₹299 per share.
The offer, triggered by a Share Purchase Agreement to acquire a 43